WEBULL
News
ALKS
27.81
-0.82%
-0.23
Analysts Have Conflicting Sentiments on These Healthcare Companies: BioCryst (BCRX), Wave Life Sciences (WVE) and Alkermes (ALKS)
TipRanks · 18h ago
Tracking Baker Brothers Portfolio - Q3 2025 Update
Seeking Alpha · 2d ago
Weekly Report: what happened at ALKS last week (1208-1212)?
Weekly Report · 3d ago
Healthcare Dashboard For December And Focus On PJP
Seeking Alpha · 4d ago
HSR Waiting Period Expires for Avadel Pharmaceuticals Acquisition by Alkermes
Reuters · 12/09 21:16
Alkermes (ALKS) Gets a Hold from Bank of America Securities
TipRanks · 12/09 12:06
Weekly Report: what happened at ALKS last week (1201-1205)?
Weekly Report · 12/08 10:22
Alkermes EVP R&D and Chief Medical Officer Craig C. Hopkinson Reports Disposal of Common Shares
Reuters · 12/05 21:22
Alkermes To Acquire Avadel Pharmaceuticals In Shareholder Scheme, Sends Proposal To Equity And Employee Share Purchase Plan Holders
Benzinga · 12/05 21:03
Should Strong Q3 Results and Raised 2025 Guidance Require Action From Alkermes (ALKS) Investors?
Simply Wall St · 12/02 08:16
Alkermes EVP R&D and Chief Medical Officer Craig C. Hopkinson Reports Disposal of Common Shares
Reuters · 12/01 22:42
AVADEL PHARMACEUTICALS PLC - SCHEME MEETING AND EGM SCHEDULED FOR JANUARY 12, 2026
Reuters · 12/01 21:06
Centessa price target raised to $42 from $33 at B. Riley
TipRanks · 12/01 13:35
Weekly Report: what happened at ALKS last week (1124-1128)?
Weekly Report · 12/01 10:18
A Look at Alkermes (ALKS) Valuation Following Q3 Earnings Beat and Raised 2025 Outlook
Simply Wall St · 11/30 17:11
Jefferies expects Avadel-Alkermes deal to close
TipRanks · 11/26 21:05
Alkermes plc to Participate in Upcoming Investor Conferences
Reuters · 11/25 21:00
Weekly Report: what happened at ALKS last week (1117-1121)?
Weekly Report · 11/24 10:22
Are Investors Missing Alkermes' Value After Five Years of 57% Growth?
Simply Wall St · 11/23 09:23
AGIO Stock Hits 52-Week Low on Mixed Sickle Cell Disease Study Results
NASDAQ · 11/20 17:33
More
Webull provides a variety of real-time ALKS stock news. You can receive the latest news about Alkermes Plc through multiple platforms. This information may help you make smarter investment decisions.
About ALKS
Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.